申请人:HUDSON BIOPHARMA INC.
公开号:US20150322076A1
公开(公告)日:2015-11-12
Described are spiropyrrolidines (I) useful as inhibitors of MDM2/p53 interactions and provides useful agents for the treatment of diseases like cancer and retinal macular degeneration diseases. The invented compounds herein have the general
Further described are pharmaceutical compositions that comprise one or more compounds of the invention, a pharmaceutically acceptable salt or pro-drug and/or a pharmaceutically acceptable carrier or excipient.
描述了作为MDM2/p53相互作用抑制剂的螺环吡咯烷(I),并提供了用于治疗癌症和视网膜黄斑变性等疾病的有用药剂。本发明的化合物具有一般性。进一步描述了包括本发明的一个或多个化合物、药学上可接受的盐或前药以及药学上可接受的载体或赋形剂的药物组合物。